All Clinical Trials

A listing of 23153 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment

NCT06104280

Recruiting

Opioid use disorder (OUD) is a treatable medical illness with three medications FDA approved for treatment. However, persons with OUD report significant sleep disturbance, even when treated with medications for opioid use disorder, leading to high rates of relapse. In this project, we will investigate a special set of photosensitive neurons in the retina as an underlying mechanism for circadian rhythm and sleep disturbance from opioid use and medications for OUD that could lead to novel interven... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

04/09/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +1 locations

Conditions: Opioid Use Disorder, Sleep Disturbance

Learn More ›

Cryotherapy & Oxaliplatin

NCT06281925

Recruiting

The primary objective of this study is to determine if cryotherapy is beneficial to patients with colon cancer who are receiving oxaliplatin in the prevention of developing chemotherapy induced peripheral neuropathy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/09/2025

Locations: NYU Langone Health, Mineola, New York +1 locations

Conditions: Colon Cancer, Peripheral Neuropathy

Learn More ›

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062

Recruiting

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents. The current subprotocols include the following: Subprotocol A: RMC-6236 + 5-fluorouracil-based regimens Subprotocol B: RMC-6236 + cetuximab with or without mFOLFOX6 Subprotocol C: RMC-6236 + gemcitabine + nab-paclitaxel Subprotocol D: RMC-9805 with or without RMC-6236 +... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/09/2025

Locations: Mayo Clinic Hospital, Phoenix, Arizona +21 locations

Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma

Learn More ›

A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Ulcerative Colitis

NCT06588855

Recruiting

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with RO7790121 compared with placebo in participants with moderately to severely active ulcerative colitis (UC).

Gender:

ALL

Ages:

Between 16 years and 80 years

Trial Updated:

04/09/2025

Locations: Om Research LLC, Apple Valley, California +102 locations

Om Research LLC, Apple Valley, California

Valley View Internal Medicine, Garden Grove, California

Gastro Care Associates, Lancaster, California

Hi Tech and Global Research, LLC, Coral Gables, Florida

LCC Medical Research Institute, LLC, Miami, Florida

Ambert Medical Research, Miami, Florida

Gastroenterology Institute of Orlando, Orlando, Florida

Digestive and Liver Center of Florida, Orlando, Florida

Guardian Angel Research Center, LLC, Tampa, Florida

Santos Research Center, CORP, Tampa, Florida

Atlanta Gastroenterology Associates, Atlanta, Georgia

Illinois Gastroenterology Group-Glenview powered by GI Alliance, Glenview, Illinois

GI Alliance - Gurnee, Gurnee, Illinois

Kansas Gastroenterology, LLC under Clinical Trials Network, Wichita, Kansas

Delta Gastroenterology & Endoscopy Center, Southaven, Mississippi

Ellipsis Research Group, Brooklyn, New York

DiGiovanna Inst for Med Ed&Res, North Massapequa, New York

Queens Village Medical Care, Queens Village, New York

Gastroenterology Group of Rochester under CTNx, Rochester, New York

Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte, North Carolina

Omega Research North Carolina, LLC, Fuquay-Varina, North Carolina

Dayton Gastroenterology, Inc., Beavercreek, Ohio

University of Cincinnati Hospital, Cincinnati, Ohio

Ohio State University, Hilliard, Ohio

Frontier Clinical Re search, LLC, Uniontown, Pennsylvania

Gastroenterology Associates, PA PA of Greenville, Greenville, South Carolina

Amel Med LLC, Georgetown, Texas

Cano Medical Center, Harlingen, Texas

Texas Digestive Specialists, Harlingen, Texas

Emeritas Research Group, Lansdowne Town Center, Virginia

Hospital Britanico, Ciudad Autonoma Bs As, Not set

Instituto Medico CER, Quilmes, Not set

Macquarie University Hospital, Macquarie Park, New South Wales

Coral Sea Clinical Research Institute, Mackay, Queensland

Footscray Hospital, Footscray, Victoria

Royal Melbourne Hospital, Parkville, Victoria

Ordensklinikum Linz Barmherzige Schwestern, Linz, Not set

Klinikum Wels-Grieskirchen, Wels, Not set

AZORG Campus Aalst-Moorselbaan, Aalst, Not set

CHU St Pierre (St Pierre), Brussels, Not set

Cliniques Universitaires St-Luc, Bruxelles, Not set

London Health Sciences Centre Uni Campus, London, Ontario

Centro de Investigación Clínica UC-CICUC, Santiago, Not set

Third Xiangya Hospital Centrel South University, Changsha, Not set

West China Hospital of Sichuan University, Chengdu City, Not set

The second Affiliated Hospital of Guangzhou Medical University, Guangzhou City, Not set

Guangzhou First People's Hospital, Guangzhou, Not set

Sir Run Run Shaw Hospital Zhejiang University, Hangzhou City, Not set

Huizhou Central People's Hospital, Huizhou, Not set

The First Affilliated Hospital of Kunming Medical University, Kunming, Not set

The Second Affiliated Hospital of Nanchang University, Nanchang City, Not set

The First Affiliate Hospital of Guangxi Medical University, Nanning, Not set

The First Affiliated Hospital of Ningbo University, Ningbo City, Not set

The Affiliated Hospital of Medical College Qingdao University, Qingdao, Not set

Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai City, Not set

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Not set

Shengjing Hospital of China Medical University, ShenYang, Not set

First Affiliated Hospital of Soochow University, Suzhou, Not set

The First Affiliated Hospital of Xiamen University, Xiamen, Not set

Zhongshan Hospital Xiamen University, Xiamen, Not set

Fakultni nemocnice Ostrava, Ostrava - Poruba, Not set

Ålborg Universitets Hospital, Ålborg, Not set

CHU Tours - Hôpital Trousseau, Chambray les Tours, Not set

CHU Clermont Ferrand - Hôtel Dieu, Clermont-Ferrand, Not set

Hôpital Henri Mondor, Créteil, Not set

Polyclinique Grand Sud, Nimes, Not set

Hôpital de Brabois Adultes, Vandoeuvre-les-nancy, Not set

Universitätsklinikum Heidelberg, Heidelberg, Not set

Medizinisches Zentrum Klinikum Lueneburg, Lueneburg, Not set

Észak-Pesti Centrumkórház-Honvédkórház, Budapest, Not set

Vasutegeszsegugyi Kft. - Debreceni Egeszsegugyi Kozpont, Debrecen, Not set

Vas-Oxy Egeszsegugyi Kft, Szombathely, Not set

Fejer Varmegyei Szent György Egyetemi Oktatokorhaz, Székesfehérvár, Not set

Policlinico Universitario Campus Biomedico Di Roma, Roma, Lazio

Ospedale Isola Tiberina Gemelli, Roma, Lazio

FAICIC S de R.L. de C.V, Veracruz, Not set

ETZ Elisabeth, Tilburg, Not set

Medical Center Kermed, Bydgoszcz, Not set

MZ Badania Slowik Zymla Sp.j., Knurów, Not set

Centrum Medyczne Promed, Kraków, Not set

Medrise sp z o.o, Lublin, Not set

EMC Instytut Medyczny SA, Pozna?, Not set

Gabinety Lekarskie Rivermed, Pozna?, Not set

Clinical Research Center Sp. z o.o. MEDIC-R Spó?ka Komandytowa, Pozna?, Not set

Endoskopia Sp. z o.o., Sopot, Not set

Sonomed Sp. z o.o., Szczecin, Not set

Centrum Zdrowia-MDM, Warszawa, Not set

Medon Clinical Research sp. z o.o, Warszawa, Not set

PlanetMed sp. z o.o., Wroc?aw, Not set

Hospital de Braga, Braga, Not set

Hospital da Luz Lisboa, Lisboa, Not set

Centro Hospitalar do Algarve - Hospital de Portimao, Portimao, Not set

Hospital de Sao Joao, Porto, Not set

Centro Hospitalar de Entre Douro e Vouga - H. São Sebastião, Santa Maria Da Feira, Not set

Hospital Sao Teotonio, Viseu, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid

Division of Gastroenterology, Depart of Internal Med., Fac of Med., Chiang Mai University, Chiang Mai, Not set

Burapha University Hospital, Chonburi, Not set

Sunpasitthiprasong Hospital, Ubonratchathani, Not set

Leicester General Hospital, Leicester, Not set

Bronglais General Hospital, Llanrhystud, Not set

Stepping Hill Hospital, Stockport, Not set

New Cross Hospital, Wolverhampton, Not set

Conditions: Moderately to Severely Active Ulcerative Colitis

Learn More ›

Substance Misuse and Family Violence Treatment Fathers

NCT06650267

Recruiting

This study involves a randomized controlled trial of Fathers for Change (F4C) compared to Individual Drug Counseling (IDC) with a sample of 280 fathers enrolled in substance use (SU) treatment within community or veterans (VA) healthcare settings to (a) demonstrate F4C efficacy compared to IDC in reducing SU and family violence (FV) at end of treatment, 3- and 6-month post-treatment follow-up, and (b) document improved emotion regulation as the mechanism within F4C that results in reduced SU and... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

04/09/2025

Locations: Yale University Child Study Center, New Haven, Connecticut +1 locations

Conditions: Substance Misuse, Violence, Domestic, Child Abuse

Learn More ›

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

NCT06764485

Recruiting

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.

Gender:

MALE

Ages:

18 years and above

Trial Updated:

04/09/2025

Locations: Local Institution - 0330, Birmingham, Alabama +236 locations

Local Institution - 0330, Birmingham, Alabama

Local Institution - 0329, Gilbert, Arizona

Local Institution - 0015, La Jolla, California

Local Institution - 0224, Los Alamitos, California

Local Institution - 0370, Los Angeles, California

Local Institution - 0364, Los Angeles, California

Local Institution - 0016, San Francisco, California

Local Institution - 0411, San Francisco, California

Local Institution - 0238, Aurora, Colorado

Rocky Mountain Cancer Centers, LLP, Denver, Colorado

Local Institution - 0413, Washington, District of Columbia

Local Institution - 0077, Athens, Georgia

Local Institution - 0048, Chicago, Illinois

Local Institution - 0331, Westwood, Kansas

Local Institution - 0060, Wichita, Kansas

Local Institution - 0019, Baltimore, Maryland

Local Institution - 0344, Frederick, Maryland

Local Institution - 0054, Towson, Maryland

Local Institution - 0104, Minneapolis, Minnesota

Local Institution - 0049, Las Vegas, Nevada

Local Institution - 0334, Albuquerque, New Mexico

Local Institution - 0081, Albuquerque, New Mexico

Local Institution - 0197, Buffalo, New York

Local Institution - 0412, Mineola, New York

Local Institution - 0069, New York, New York

Local Institution - 0076, New York, New York

Local Institution - 0085, New York, New York

Local Institution - 0071, New York, New York

Local Institution - 0225, Syracuse, New York

Local Institution - 0056, Columbus, Ohio

Local Institution - 0067, Portland, Oregon

Local Institution - 0416, Portland, Oregon

Local Institution - 0345, Philadelphia, Pennsylvania

Local Institution - 0414, Philadelphia, Pennsylvania

Local Institution - 0057, Philadelphia, Pennsylvania

Local Institution - 0349, Willow Grove, Pennsylvania

Local Institution - 0055, Charleston, South Carolina

Carolina Urologic Research Center, LLC, Myrtle Beach, South Carolina

Local Institution - 0335, Nashville, Tennessee

Local Institution - 0114, Austin, Texas

Local Institution - 0018, Austin, Texas

Local Institution - 0042, Houston, Texas

Local Institution - 0220, Houston, Texas

Local Institution - 0109, Murray, Utah

University of Virginia Cancer Center, Charlottesville, Virginia

Local Institution - 0023, Richmond, Virginia

Local Institution - 0078, Seattle, Washington

Local Institution - 0293, Vancouver, Washington

Local Institution - 0112, Milwaukee, Wisconsin

Local Institution - 0125, Caba, Buenos Aires

Local Institution - 0124, Ciudad Autónoma de Buenos Aires, Buenos Aires

Local Institution - 0128, ABB, Ciudad Autónoma De Buenos Aires

Local Institution - 0130, Río Cuarto, Córdoba

Local Institution - 0136, Viedma, R

Local Institution - 0129, Buenos Aires, Not set

Local Institution - 0235, Cordoba, Not set

Local Institution - 0366, Campbelltown, New South Wales

Local Institution - 0359, Darlinghurst, New South Wales

Local Institution - 0356, Macquarie University, New South Wales

Port Macquarie - Mid North Coast Cancer Institute, Port Macquarie, New South Wales

Sydney Adventist Hospital, Wahroonga, New South Wales

Greenslopes Private Hospital - Gallipoli Medical Research Foundation, Greenslopes, Queensland

Tasman Oncology Research, Southport, Queensland

Local Institution - 0362, Adelaide, South Australia

Lyell McEwin Hospital, Elizabeth Vale, South Australia

Local Institution - 0352, Kurralta Park, South Australia

Local Institution - 0354, Hobart, Tasmania

Local Institution - 0363, Heidelberg, Victoria

Local Institution - 0353, Malvern, Victoria

Local Institution - 0348, Melbourne, Victoria

Local Institution - 0361, Melbourne, Victoria

Local Institution - 0357, Murdoch, Western Australia

Local Institution - 0369, Krems, Niederösterreich

Local Institution - 0373, Linz, Oberösterreich

Local Institution - 0367, Salzburg, Not set

Local Institution - 0368, Wien, Not set

Local Institution - 0039, Vitória, Espírito Santo

Local Institution - 0025, Belo Horizonte, Minas Gerais

Local Institution - 0035, Natal, Rio Grande Do Norte

Local Institution - 0026, Porto Alegre, Rio Grande Do Sul

Local Institution - 0395, Sao Paulo, São Paulo

Local Institution - 0031, Sao Paulo, São Paulo

Local Institution - 0304, Kelowna, British Columbia

Local Institution - 0152, Vancouver, British Columbia

Local Institution - 0151, Halifax, Nova Scotia

Local Institution - 0193, Toronto, Ontario

Local Institution - 0093, Chicoutimi, Quebec

Local Institution - 0305, Montréal, Quebec

Local Institution - 0150, Quebec City, Quebec

Centre intégré de santé et de services sociaux du Bas Saint-Laurent- Hôpital régional de Rimouski, Rimouski, Quebec

Local Institution - 0135, Santiago, Región Metropolitana De Santiago

Local Institution - 0132, Santiago, Región Metropolitana De Santiago

Local Institution - 0127, Viña del Mar, Valparaíso

Local Institution - 0232, Hefei, Anhui

Local Institution - 0168, Beijing, Beijing

Local Institution - 0192, Beijing, Beijing

Local Institution - 0176, Beijing, Beijing

Local Institution - 0237, Chongqing, Chongqing

Local Institution - 0249, Fuzhou, Fujian

Local Institution - 0213, Xiamen, Fujian

Local Institution - 0226, Guangzhou, Guangdong

Local Institution - 0180, Guangzhou, Guangdong

Local Institution - 0415, Huizhou, Guangdong

Local Institution - 0222, Harbin, Heilongjiang

Local Institution - 0211, Zhengzhou, Henan

Local Institution - 0279, Zhengzhou, Henan

Local Institution - 0284, Wuhan, Hubei

Local Institution - 0216, Changsha, Hunan

Local Institution - 0217, Changsha, Hunan

Local Institution - 0233, Nanjing, Jiangsu

Local Institution - 0228, Nanjing, Jiangsu

Local Institution - 0229, Nanjing, Jiangsu

Local Institution - 0219, Nanchang, Jiangxi

Local Institution - 0198, Xi'an, Shaanxi

Local Institution - 0191, Jinan, Shandong

Local Institution - 0221, Yantai, Shandong

Local Institution - 0300, Shanghai, Shanghai

Local Institution - 0212, Shanghai, Shanghai

Local Institution - 0214, Shanghai, Shanghai

Local Institution - 0215, Shanghai, Shanghai

Local Institution - 0308, Shanghai, Shanghai

Local Institution - 0205, Taiyuan, Shanxi

Local Institution - 0278, Cheng Du, Sichuan

Local Institution - 0240, Chengdu, Sichuan

Local Institution - 0283, Chengdu, Sichuan

Local Institution - 0218, Urumqi, Xinjiang

Local Institution - 0181, Hangzhou, Zhejiang

Local Institution - 0196, Hangzhou, Zhejiang

Local Institution - 0280, Hangzhou, Zhejiang

Local Institution - 0281, Linhai, Zhejiang

Local Institution - 0223, Wenzhou, Zhejiang

Local Institution - 0011, Horovice, Beroun

Local Institution - 0008, Brno, Brno-město

Local Institution - 0005, Hradec Kralove, Hradec Králové

Local Institution - 0010, Olomouc, Olomoucký Kraj

Local Institution - 0009, Prague, Praha 2

Local Institution - 0004, Praha, Praha 5

Local Institution - 0006, Praha 2, Not set

Local Institution - 0243, Copenhagen, Hovedstaden

Local Institution - 0098, Copenhagen, Hovedstaden

Local Institution - 0396, Aarhus, Midtjylland

Local Institution - 0100, Aalborg, Nordjylland

Local Institution - 0167, Nice, Alpes-Maritimes

Local Institution - 0169, Strasbourg, Alsace

Local Institution - 0307, Toulouse, Haute-Garonne

Local Institution - 0177, Vandoeuvre-lès-Nancy, Lorraine

Local Institution - 0166, Pierre-Bénite, Rhône

Local Institution - 0231, Le Mans, Sarthe

Local Institution - 0179, Villejuif, Val-de-Marne

Local Institution - 0165, Clermont-Ferrand, Not set

Local Institution - 0178, Paris, Not set

Local Institution - 0374, München, Bayern

Local Institution - 0371, Lübeck, Schleswig-Holstein

Local Institution - 0380, Jena, Thüringen

Local Institution - 0382, Bonn, Not set

Local Institution - 0375, Essen, Not set

Local Institution - 0378, Hamburg, Not set

Local Institution - 0379, Heidelberg, Not set

Local Institution - 0377, Herne, Not set

Local Institution - 0376, Tübingen, Not set

Local Institution - 0372, Wuerzburg, Not set

Local Institution - 0271, Cork, Not set

Local Institution - 0272, Dublin, Not set

Local Institution - 0273, Dublin, Not set

Local Institution - 0157, Milan, Lombardia

Local Institution - 0234, Orbassano, Piemonte

Local Institution - 0155, Rome, Roma

Local Institution - 0153, Padova, Veneto

Local Institution - 0156, Arezzo, Not set

Local Institution - 0409, Foggia, Not set

Local Institution - 0160, Napoli, Not set

Local Institution - 0159, Terni, Not set

Local Institution - 0158, Trento, Not set

Local Institution - 0389, Goyang-si, Kyǒnggi-do

Local Institution - 0386, Seongnam, Kyǒnggi-do

Local Institution - 0385, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0387, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0388, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0384, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0346, Wroclaw, Dolnośląskie

Local Institution - 0187, Warszawa, Mazowieckie

Local Institution - 0190, Opole, Opolskie

Local Institution - 0186, Gdansk, Pomorskie

Local Institution - 0365, Skorzewo, Wielkopolskie

Local Institution - 0189, Bydgoszcz, Not set

Local Institution - 0336, Katowice, Not set

Local Institution - 0185, Bytom, Śląskie

BRCR Global - Mayagüez, Mayaguez, Not set

Local Institution - 0139, Craiova, Dolj

Local Institution - 0144, Cluj, Not set

Local Institution - 0145, Cluj, Not set

Local Institution - 0141, Iași, Not set

Local Institution - 0142, Ploiești, Not set

Local Institution - 0275, Banska Bystrica, Banskobystrický Kraj

Local Institution - 0381, Prešov, Prešovský Kraj

Local Institution - 0201, Bratislava, Not set

Local Institution - 0200, Martin, Žilinský Kraj

Local Institution - 0312, Cordoba, Andalucía

Local Institution - 0310, Barcelona, Barcelona [Barcelona]

Local Institution - 0311, Sabadell, Barcelona [Barcelona]

Local Institution - 0325, Barakaldo, Bizkaia

Local Institution - 0314, Santander, Cantabria

Local Institution - 0315, Barcelona, Catalunya [Cataluña]

Local Institution - 0319, Lugo, Lugo [Lugo]

Local Institution - 0321, Madrid, Madrid, Comunidad De

Local Institution - 0316, Madrid, Madrid, Comunidad De

Local Institution - 0317, Madrid, Madrid, Comunidad De

Local Institution - 0323, Madrid, Madrid, Comunidad De

Local Institution - 0326, Majadahonda, Madrid, Comunidad De

Local Institution - 0406, Pamplona, Navarra

Local Institution - 0407, Ourense, Ourense [Orense]

Local Institution - 0320, Badajoz, Not set

Local Institution - 0328, Burgos, Not set

Local Institution - 0318, Granada, Not set

Local Institution - 0309, Madrid, Not set

Local Institution - 0327, Málaga, Not set

Local Institution - 0322, Sevilla, Not set

Local Institution - 0313, Sevilla, Not set

Local Institution - 0324, València, Not set

Local Institution - 0099, Lund, Skåne Län [se-12]

Local Institution - 0408, Solna, Stockholms Län [se-01]

Local Institution - 0097, Uppsala, Uppsala Län [se-03]

Local Institution - 0095, Gothenburg, Västra Götalands Län [se-14]

Local Institution - 0398, Taichung, Not set

Local Institution - 0399, Taipei, Not set

Local Institution - 0397, Taipei, Not set

Local Institution - 0340, Adana, Not set

Local Institution - 0339, Ankara, Not set

Local Institution - 0341, Ankara, Not set

Local Institution - 0338, Ankara, Not set

Local Institution - 0337, Istanbul, Not set

Local Institution - 0342, Istanbul, Not set

Local Institution - 0393, Glasgow, Glasgow City

Local Institution - 0383, Northwood, Hillingdon

St Bartholomew's Hospital, London, London, City Of

Local Institution - 0391, London, Sutton

Local Institution - 0248, Manchester, Not set

Conditions: Metastatic Castration-resistant Prostate Cancer

Learn More ›

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

NCT06908954

Recruiting

The main aim of this study is to understand how moderate and severe liver impairment (based on the Child-Pugh classification) affects the body's processing of a single dose of 10 mg maximum of palovarotene, compared to healthy participants with normal liver function. The study will also assess the safety and tolerability of the single dose of palovarotene. Participants will be enrolled in stages and divided into three groups based on their liver function: * Group 1: Healthy participants with... Read More

Gender:

ALL

Ages:

Between 18 years and 70 years

Trial Updated:

04/09/2025

Locations: ERG - Clinical Pharmacology of Miami, Miami, Florida +2 locations

Conditions: Hepatic Impairment, Healthy

Learn More ›

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

NCT03114462

Recruiting

To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/09/2025

Locations: MD Anderson Cancer Center, Houston, Texas

Conditions: Malignant Neoplasms of Respiratory and Intrathoracic Organs, Squamous Cell Carcinoma of the Larynx

Learn More ›

Talus Replacement Registry

NCT03965143

Recruiting

Avascular necrosis of the talus is a difficult problem to manage, especially in the young and healthy. The only option, historically, has been a talectomy and hindfoot fusion. While this is a viable option, it is not without its morbidity. Arthritis of surrounding joints is common, occurring anywhere from 1-10 years after the procedure. This is especially true in younger patients, where loss of motion can be life altering both physically and mentally. The search for alternatives has been limited. Recently, 3D printing has become more ubiquitous and affordable and newer medical alternatives have arisen thanks to this technology. The 3D custom talus is relatively new in the orthopaedic community, but has been used at several centers with good success. It has been shown to re-establish the normal alignment of the foot, preserve motion (with some achieving almost physiologic motion), and allow for almost normal ambulation. However, the data is still limited and further study is necessary. Our facility was recently approved to perform this procedure. Our hypothesis is that custom 3D printed talar body replacements, either used alone or with total ankle replacements, will maintain physiologic motion, have no difference in complications when compared to hindfoot fusions with allograft, lead to good outcome scores and patient satisfaction scores. Patients diagnosed with avascular necrosis of the talus who have already decided to undergo a procedure involving a 3D custom talus as part of their standard care (talar replacement, total ankle/total talus, etc) will be enrolled in the study. Patients will follow standard post-operative protocols and return to clinic at designated time periods (2 weeks, 6 weeks, 3 months, 6 months, 1 year). X-ray evaluation, Range of motion, return to ambulation, walking speed and patient reported outcomes will be evaluated at each visit. Data will then be compared with baseline measurements and use to determine the progression of patients over time after the procedure Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/09/2025

Locations: University of Missouri, Columbia, Missouri

Conditions: Avascular Necrosis of the Talus

Learn More ›

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

NCT04471727

Recruiting

This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/09/2025

Locations: Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California +10 locations

Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma

Learn More ›

Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies

NCT04888338

Recruiting

This study collects information on outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies. Collecting information from patients before, during, and after receiving chimeric antigen receptor therapy or radiation therapy may help doctors to optimize patient selection, dose, timing, and sequencing of these treatments.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/09/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Learn More ›

Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy

NCT05198245

Recruiting

The purpose of the study is to evaluate the risk of pregnancy and infant outcomes among women with migraine exposed to rimegepant during pregnancy and in two rimegepant unexposed comparator groups.

Gender:

FEMALE

Ages:

Between 16 years and 49 years

Trial Updated:

04/09/2025

Locations: Research Triangle Institute d/b/a RTI Health Solutions, Research Triangle Park, North Carolina

Conditions: Migraine

Learn More ›